HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s ADC I-DXd Shows Distinct Safety Profile in SCLC: R&D Head
September 22, 2025
- Allergan Seeks Label Expansion for Botox Vista in Japan
September 22, 2025
- Takeda to Ship Medicines via Wind-Powered Vessel from 2026
September 22, 2025
- Nippon Shinyaku’s DMD Med Bags Orphan Status in US
September 22, 2025
- Kisunla Uptake “as Expected” One Year after Approval, Says Lilly Japan Exec
September 19, 2025
- SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026
September 19, 2025
- Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy
September 19, 2025
- Lilly Japan Adds Tablet Formulation for Retevmo
September 19, 2025
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- Eisai’s Etalanetug Snags FDA Fast Track Designation
September 18, 2025
- Daito Wins China Approval for Celecoxib, 2nd Generic in Market
September 18, 2025
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
- Kyorin/aTyr’s Efzofitimod Misses Primary Goal in Global PIII Trial
September 17, 2025
- Mitsubishi, J&J to End Stelara Co-Promotion in Japan at Year-End
September 17, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- Daiichi Bags FDA Breakthrough Therapy Status for Anti-CDH6 ADC
September 17, 2025
- AbbVie Japan Seeks Rinvoq Label Expansion for Polyarticular JIA
September 16, 2025
- Clenafin Authorized Generic Hits Japan Market: Kaken
September 16, 2025
- Lilly Confirms Safety of Oral GLP-1 Orforglipron in Japan PIII
September 16, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
